A new clinical trial is set to investigate the effects of OptiCreatine on plasma creatine levels and digestive health in adult participants, including both males and females. Sponsored by TSI Group LTD and the University of North Carolina, this study aims to provide evidence for the comparative effectiveness of OptiCreatine versus creatine monohydrate supplements. Professionals in clinical research, regulatory compliance, and product evaluation should follow this emerging study closely for its implications in dietary supplement developments and medical applications.
In this article:
- What is the purpose of the trial?
- Interventions and trial protocol
- What are the next steps?
- FAQ
- Conclusion
- Disclaimer
- Announcement link
What is the purpose of the trial?
The upcoming clinical trial will examine the role of OptiCreatine, a dietary supplement, in enhancing plasma creatine levels in healthy adults. Researchers aim to assess its absorption efficiency compared to creatine monohydrate supplements. This study will also investigate any associated gastrointestinal effects in both male and female participants, providing critical data on how these supplements impact digestive health and overall safety.
Interventions and trial protocol
The trial’s design incorporates two distinct interventions:
- OptiCreatine: Participants will receive doses of this novel dietary supplement to measure its ability to increase plasma creatine levels.
- Creatine Monohydrate: As a control comparison, the study will also administer the traditional creatine monohydrate supplement.
Both interventions aim to identify differences in absorption rates and digestive side effects. The study population includes healthy adults from diverse backgrounds, ensuring results are applicable to a broad demographic.
The trial will be conducted under stringent regulatory-compliant conditions and is currently listed as not yet recruiting on ClinicalTrials.gov. This status suggests that the enrollment phase is pending, and further updates will be necessary as the process advances.
What are the next steps?
Once recruitment begins, researchers will select eligible participants based on predefined inclusion criteria designed to eliminate variables that could affect creatine absorption or bias digestive health results. Preliminary findings are expected after the initial phases, providing industry stakeholders with insight into the efficacy and tolerability of OptiCreatine.
Clinical and regulatory teams should monitor this trial as it progresses. Results may influence dietary supplement regulations, labeling requirements, and consumer guidance, potentially impacting market dynamics and product development.
FAQ
1. Who sponsors the trial?
The trial is sponsored by TSI Group LTD and the University of North Carolina.
2. What supplements will be studied?
OptiCreatine and creatine monohydrate are the two dietary supplements being tested.
3. When will recruitment start?
As of now, the study is marked “not yet recruiting” on ClinicalTrials.gov.
4. Are both genders included in the trial?
Yes, the trial includes both male and female participants.
Conclusion
This clinical trial could deliver valuable information on creatine supplementation’s impact on health. For industry professionals, the data may refine understanding of absorption mechanisms and gastrointestinal health effects, assisting future regulatory assessments.
Disclaimer
This article is for informational purposes. It is not legal advice and should not replace thorough consultation with regulatory or clinical experts.
Announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07225335?term=medical+device